This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Seattle Children's Hospital Dba Seattle Children's Research Institute. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Dimiter Stanchev Dimitrov and His Patent in Cancer Immunotherapy.
Introduction
Dimiter Stanchev Dimitrov is an inventor associated with Pittsburgh, Pennsylvania. His patent work concerns binders and chimeric antigen receptors designed to specifically bind fibroblast growth factor receptor 4 (FGFR4), a target studied in cancer research.
Latest Patents
Dimitrov is listed as an inventor on one patent: “Binders and Chimeric Antigen Receptors Which Specifically Bind Fibroblast Growth Factor Receptor 4.” The invention focuses on binding molecules and engineered immune-cell receptors that recognize FGFR4. The supplied information does not establish the patent’s filing or grant date, so it cannot be identified as his latest patent by date. His reported portfolio includes 1 patent.
Career Highlights
Dimitrov is associated with Seattle Children’s Research Institute, which operates as part of Seattle Children’s. His listed patent reflects research into targeted approaches that may support the development of cancer immunotherapies.
Collaborations
Rimas J. Orentas and Wei Li are identified as Dimitrov’s coworkers. Their association provides context for the collaborative research environment connected with his patent work.
Conclusion
Dimiter Stanchev Dimitrov’s documented invention centers on FGFR4-targeting binders and chimeric antigen receptors, linking his patent record to research with potential relevance to cancer immunotherapy.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile